KCT0002910已完成未知
RAndomized Comparison of efficacy and safety of lipid-lowerING with statin monotherapy versus statin/ezetimibe combination for high-risk cardiovascular diseases (RACING trial)
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 3,780
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19?(Year) 至 80?(Year)（—）
- 性别
- All
入选标准
- •1. Age 19-80 years
- •2. Documented CVD, previous MI, ACS, coronary revascularization and other arterial revascularization procedures, ischemic stroke, or PAD
排除标准
- •1. Active liver disease or persistent unexplained serum AST or ALT elevation more than 2 times the upper limit of normal range
- •2. Allergy or hypersensitivity to any statin or ezetimibe
- •3. Solid organ transplantation recipient
- •4. History of any adverse drug reaction requiring discontinuation of statin
- •5. Pregnant women, women with potential childbearing, or lactating women
- •6. Life expectancy less than 3 years
- •7. Inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator
- •8. Inability to understand or read the informed content
研究者
相似试验
已完成
3 期
osartan - Metoprolol XL Combination in Essential Hypertension Along with Type II DiabetesCTRI/2011/08/001937Ipca Laboratories Ltd158
已完成
3 期
Comparative study of the safety and efficacy of levofloxacin and ciprofloxacin in the treatment of community-acquired, bacterial urinary tract infection among patients with chronic kidney diseaseKidney DiseasePACTR202401622249032Dhikrullah Adebayo90
进行中（未招募）
不适用
A study of the efficacy, safety, and quality of life (QOL) in patients with chronic idiopathic urticaria dosed with AERIUS Tablets (5 mg, 10 mg, or 20 mg once daily). - ACCESubjects with an active episode of chronic idiopathic urticaria (CIU) and are taking a second-generation antihistamine will be selected for the study. The urticaria activity score (UAS) must be between 10-30, inclusive, at the end of the baseline week (entry period).MedDRA version: 8.1Level: LLTClassification code 10021247Term: Idiopathic urticariaEUCTR2006-001449-33-SESchering Plough Institute, A Division of Schering Corporation600
进行中（未招募）
不适用
A study of the efficacy, safety, and quality of life (QOL) in patients with chronic idiopathic urticaria dosed with AERIUS Tablets (5 mg, 10 mg, or 20 mg once daily). - ACCEEUCTR2006-001449-33-CZSchering-Plough Research Institute, A Division of Schering Corporation600
进行中（未招募）
1 期
A study of the efficacy, safety, and quality of life (QOL) in patients with chronic idiopathic urticaria dosed with AERIUS Tablets (5 mg, 10 mg, or 20 mg once daily). Estudio de la eficacia, seguridad y calidad de vida (cdv) en pacientes con urticaria crónica idiopática tratados con aerius comprimidos (5, 10 ó 20 mg) una vez al día - ACCESubjects with an active episode of chronic idiopathic urticaria (CIU) and are taking a second-generation antihistamine will be selected for the study. The urticaria activity score (UAS) must be between 10-30, inclusive, at the end of the baseline week (entry period).MedDRA version: 8.1 Level: LLT Classification code 10021247 Term: Idiopathic urticariaEUCTR2006-001449-33-ESIntegrated Therapeutics Group Incorporated (ITGI)600